PridCor Therapeutics Reports Positive Long COVID Case Series with Combination Antiviral Regimen
New Preprint: PridCor Therapeutics LLC has released a pre-print detailing a case series of 15 patients with Long COVID (LC) who were given a continuous regimen of 120-days of valacyclovir and celecoxib with a pulsed 15-day treatment of Paxlovid (combination antiviral treatment, or CAR), and these patients were compared to 12 patients with Long COVID who received the 120-day valacyclovir and celecoxib protocol only. This CAR appeared superior to the valacyclovir and celecoxib combination in improving self-reported fatigue, dysautonomia and brain fog in these LC patients.
– This preprint suggests that CAR has both an excellent safety profile as well as a remarkable efficacy in PGIC data reversing fatigue, the primary endpoint (p<0.0001). The use of CAR also showed superior reduction in the secondary endpoints of dysautonomia and brain fog when compared to valacyclovir and celecoxib alone.
-The CAR patients were reassessed at the 305-day and 731-day follow-up from their treatment start date and reported no measurable loss of efficacy demonstrating significant durability of treatment.
– A formal double-blind, placebo-controlled, randomized clinical trial, the “SHIELD” study will be conducted at the Icahn School of Medicine at Mount Sinai (PI: David Putrino, PhD; Co-Investigator: Amy Proal, PhD) beginning late 2025/early 2026.
TUSCALOOSA, Ala., Sept. 04, 2025 (GLOBE NEWSWIRE) — PridCor Therapeutics LLC, a clinical-stage biopharmaceutical company developing novel antiviral therapies for chronic viral-driven diseases, today announced encouraging findings from a new preprint on Research Square detailing a small, open-label Long COVID (LC) case series.
In this study authored by William Pridgen, M.D. and David Putrino, Ph.D., 15 LC patients received a 15-day pulsed course of Paxlovid® in addition to a 120-day regimen of valacyclovir and celecoxib (CAR) and were compared with 12 patients who received the dual-drug regimen alone. Fatigue, the primary endpoint, improved significantly (p<0.0001) by Patient-Reported Global Impression of Change (PGIC), with secondary endpoints of dysautonomia and brain fog also showing greater improvement in the CAR group. Reported benefits were durable, with the majority of patients continuing to report improvements in fatigue, tachycardia, dizziness, and brain fog at approximately 305 and 731 days from treatment start.